The 36-month beta value for CANF is at 1.33. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CANF is 4.08M, and currently, shorts hold a 6.27% of that float. The average trading volume for CANF on March 18, 2025 was 110.29K shares.
CANF) stock’s latest price update
Can-Fite Biopharma Ltd ADR (AMEX: CANF)’s stock price has increased by 9.39 compared to its previous closing price of 1.65. However, the company has seen a 16.45% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-03 that Unlike chemotherapy with its known toxicity towards normal body systems, Namodenoson provides protective effects Ramat Gan, Israel, March 03, 2025 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the European Society of Medicine Journal published an innovative article titled: “The Neuro- Cardio- and Hepato- Protective Effects of Namodenoson are Mediated by Adiponectin”.
CANF’s Market Performance
CANF’s stock has risen by 16.45% in the past week, with a monthly rise of 17.97% and a quarterly rise of 10.74%. The volatility ratio for the week is 6.75% while the volatility levels for the last 30 days are 8.35% for Can-Fite Biopharma Ltd ADR The simple moving average for the last 20 days is 7.70% for CANF stock, with a simple moving average of -18.01% for the last 200 days.
Analysts’ Opinion of CANF
Many brokerage firms have already submitted their reports for CANF stocks, with Maxim Group repeating the rating for CANF by listing it as a “Buy.” The predicted price for CANF in the upcoming period, according to Maxim Group is $7 based on the research report published on August 11, 2017 of the previous year 2017.
Rodman & Renshaw gave a rating of “Buy” to CANF, setting the target price at $6 in the report published on August 29th of the previous year.
CANF Trading at 13.24% from the 50-Day Moving Average
After a stumble in the market that brought CANF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.51% of loss for the given period.
Volatility was left at 8.35%, however, over the last 30 days, the volatility rate increased by 6.75%, as shares surge +15.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.56% upper at present.
During the last 5 trading sessions, CANF rose by +16.13%, which changed the moving average for the period of 200-days by -21.74% in comparison to the 20-day moving average, which settled at $1.6757. In addition, Can-Fite Biopharma Ltd ADR saw 11.08% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CANF
Current profitability levels for the company are sitting at:
- -10.54 for the present operating margin
- 1.0 for the gross margin
The net margin for Can-Fite Biopharma Ltd ADR stands at -9.73. The total capital return value is set at -0.46. Equity return is now at value -142.49, with -79.22 for asset returns.
Based on Can-Fite Biopharma Ltd ADR (CANF), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -2.38. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -217.59.
Currently, EBITDA for the company is -8.18 million with net debt to EBITDA at 1.15. When we switch over and look at the enterprise to sales, we see a ratio of 37.93. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.90.
Conclusion
In conclusion, Can-Fite Biopharma Ltd ADR (CANF) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
